Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction

Dyslipidemia is one of the primary causes of cardiovascular disease. Therefore, attention has been focused on the development of drugs that normalize lipid levels and exert an effect on markers of atherothrombosis, insulin resistance (IR), and inflammation. Atorvastatin is a drug with not only lipid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruzdeva, Olga, Uchasova, Evgenya, Dyleva, Yulia, Akbasheva, Olga, Karetnikova, Victoria, Barbarash, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035767/
https://www.ncbi.nlm.nih.gov/pubmed/27725801
http://dx.doi.org/10.3389/fphar.2016.00324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035767/
https://www.ncbi.nlm.nih.gov/pubmed/27725801
http://dx.doi.org/10.3389/fphar.2016.00324

Ejemplares similares